Cabot Corp manufactures and sells a variety of chemicals, materials, and chemical-based products... Show more
The 10-day moving average for CBT crossed bullishly above the 50-day moving average on July 03, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 27, 2025. You may want to consider a long position or call options on CBT as a result. In of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CBT just turned positive on June 25, 2025. Looking at past instances where CBT's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .
CBT moved above its 50-day moving average on July 01, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CBT advanced for three days, in of 317 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 254 cases where CBT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CBT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CBT broke above its upper Bollinger Band on July 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.868) is normal, around the industry mean (3.653). P/E Ratio (12.079) is within average values for comparable stocks, (34.612). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (6.312). Dividend Yield (0.017) settles around the average of (0.037) among similar stocks. P/S Ratio (1.330) is also within normal values, averaging (97.810).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CBT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
a supplier of organic chemicals
Industry ChemicalsSpecialty
A.I.dvisor indicates that over the last year, CBT has been closely correlated with AVNT. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if CBT jumps, then AVNT could also see price increases.
Ticker / NAME | Correlation To CBT | 1D Price Change % | ||
---|---|---|---|---|
CBT | 100% | -0.71% | ||
AVNT - CBT | 72% Closely correlated | +0.03% | ||
IOSP - CBT | 66% Closely correlated | +0.67% | ||
WLK - CBT | 66% Closely correlated | -0.90% | ||
OEC - CBT | 66% Loosely correlated | +0.18% | ||
LYB - CBT | 64% Loosely correlated | -0.88% | ||
More |